4.5 Review

Neoadjuvant endocrine therapy in ER-positive breast cancer: evolution, indication, and tailored treatment strategy

Journal

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
Volume 15, Issue -, Pages -

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/17588359231200457

Keywords

breast cancer; hormone receptor-positive breast cancer; hormone therapy; luminal breast cancer; neoadjuvant therapy

Categories

Ask authors/readers for more resources

In recent years, endocrine therapy has regained interest as a neoadjuvant treatment for breast cancer. It can not only shrink tumors but also provide important clinical information on endocrine sensitivity, which is crucial for patient prognostication. Additionally, neoadjuvant endocrine therapy offers an opportunity for early assessment of novel agents' clinical efficacy.
In recent years, endocrine therapy (ET), an effective systemic treatment for the management of estrogen receptor (ER)-positive breast cancers, has regained interest as a neoadjuvant therapy based on evidence that ET can fulfill the aim of neoadjuvant systemic treatment for tumor shrinkage as well as elucidate important clinical information on endocrine sensitivity that enables the prognostication of patients. Moreover, neoadjuvant endocrine therapy (NET) potentially provides an opportunity for early assessment of the clinical efficacy of novel agents. Furthermore, recently reported trials have generated evidence for a more tailored approach for perioperative management of ER-positive breast cancer using clinical and molecular biomarkers, and this has provided a rationale that enables the broadening of clinical indications for NET. This review discusses the current evidence for NET, the evolution of NET trials, clinical indications, and NET-based treatment strategies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available